Zenas BioPharma Prices Concurrent $200M Convertible Notes and $100M Equity Offerings

summarizeSummary

Zenas BioPharma priced concurrent public offerings of $200 million in convertible senior notes and 5 million shares of common stock at $20.00 per share, raising approximately $287.4 million in net proceeds to fund its pipeline and planned commercial launch.

check_boxKey Events

• Convertible Notes Offering Priced

  Zenas BioPharma priced $200 million aggregate principal amount of 2.50% convertible senior notes due 2032, with an initial conversion price of approximately $26.50 per share. Net proceeds from the notes are estimated at $193.7 million.

• Concurrent Equity Offering Priced

  The company priced a concurrent public offering of 5 million shares of common stock at $20.00 per share. This price represents a discount to the last reported sale price of $22.16 per share on March 26, 2026. Net proceeds from the equity offering are estimated at $93.7 million.

• Significant Capital Raise

  The combined offerings are expected to generate approximately $287.4 million in net proceeds (excluding over-allotment options), providing substantial capital for the company's operations.

• Funding for Pipeline and Commercial Launch

  Proceeds will support the planned U.S. commercial launch of obexelimab for IgG4-RD (if approved) and advance the development pipeline, including orelabrutinib Phase 3 trials and ZB021 Phase 1/2 clinical development, extending the financial runway into the third quarter of 2028.

auto_awesomeAnalysis

This filing finalizes the terms and pricing of Zenas BioPharma's concurrent capital raise, which is substantial relative to its market capitalization. The equity offering was priced at a discount to the stock's closing price on March 26, 2026, leading to significant dilution for existing shareholders. While dilutive, this capital infusion is critical for the company, which previously disclosed a going concern warning, enabling the planned U.S. commercial launch of obexelimab for IgG4-RD and advancing its development pipeline. The market has already reacted negatively to the pricing, with the stock plummeting 19% following the announcement.